NCT02135133 2026-03-17A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLDana-Farber Cancer InstitutePhase 2 Completed27 enrolled 7 charts
NCT02970318 2026-02-06A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLAcerta Pharma BVPhase 3 Active not recruiting310 enrolled 18 charts 1 FDA